This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
October 24, 2011 4:30 p.m. ET
Peter Farrell - Founder, Chairman, and CEO
Don Darkin - President, SDB Strategic Business Unit
Brett Sandercock - CFO
Geoff Neilson - President, Respiratory Care Strategic Business Unit
Matthew Prior - Merrill Lynch
Ben Andrew - William Blair
David Clair - Piper Jaffray
Michael Matson - Mizuho Securities
Dan Hurren - UBS
David Low - Deutsche Bank
Good day ladies and gentlemen, and welcome to the first quarter 2012 ResMed Incorporated earnings conference call. [Operator instructions.] The company has asked me to address certain matters. First, ResMed does not authorize the recording of any portion of this conference call for any purpose.
Second, during the conference call, ResMed may make forward looking statements such as projections for future revenue or earnings, new product development, or new markets for the company’s products. These statements are made under the Safe Harbor provision of the Private Securities Litigation Reform Act of 1995.
Risks and uncertainties exist that could cause actual results to materially differ from the forward looking statements. These factors are discussed in ResMed’s SEC filings such as Forms 10-Q and 10-K, which you may access through the company’s website at www.resmed.com.
With that said, I would now like to turn the call over to Dr. Peter Farrell, ResMed’s chairman and chief executive officer. Dr. Farrell, please go ahead sir.
Thanks operator, and thanks everybody for joining us. I’ll begin with some summary comments and then turn the call over to Brett Sandercock, and then we’ll take questions and I might bring some of the other guys in as needed.